News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,276 Results
Type
Article (14326)
Company Profile (281)
Press Release (254669)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79630)
Career Advice (161)
Deals (13240)
Drug Delivery (35)
Drug Development (50478)
Employer Resources (34)
FDA (5734)
Job Trends (5144)
News (144587)
Policy (10068)
Tag
Academia (923)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21696)
ALS (69)
Alzheimer's disease (852)
Antibody-drug conjugate (ADC) (109)
Approvals (5760)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4562)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1524)
Cardiovascular disease (121)
Career advice (141)
Career pathing (2)
CAR-T (123)
Cell therapy (340)
Cervical cancer (9)
Clinical research (41183)
Collaboration (559)
Compensation (281)
Complete response letters (13)
COVID-19 (1037)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1619)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1310)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (85)
Drug pricing (30)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30138)
Editorial (20)
Employer branding (4)
Employer resources (33)
Events (48837)
Executive appointments (475)
FDA (6510)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (513)
Gene editing (102)
Generative AI (11)
Gene therapy (265)
GLP-1 (372)
Government (1097)
Grass and pollen (2)
Guidances (69)
Healthcare (6621)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1104)
Inflammatory bowel disease (119)
Inflation Reduction Act (9)
Influenza (20)
Intellectual property (69)
Interviews (22)
IPO (7284)
IRA (11)
Job creations (865)
Job search strategy (130)
Kidney cancer (7)
Labor market (8)
Layoffs (216)
Leadership (4)
Legal (1389)
Liver cancer (34)
Lung cancer (208)
Lymphoma (103)
Machine learning (5)
Management (10)
Manufacturing (147)
MASH (63)
Medical device (2610)
Medtech (2611)
Mergers & acquisitions (6296)
Metabolic disorders (406)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1278)
NextGen: Class of 2025 (2034)
Non-profit (860)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (124)
Partnered (8)
Patents (137)
Patient recruitment (83)
Peanut (35)
People (25729)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14551)
Phase II (19163)
Phase III (12100)
Pipeline (944)
Policy (51)
Postmarket research (853)
Preclinical (6162)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (298)
Real estate (1421)
Recruiting (13)
Regulatory (8698)
Reports (16)
Research institute (941)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (99)
Series B (68)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (218)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (134)
Last 7 days (616)
Last 30 days (1862)
Last 365 days (19430)
2025 (7087)
2024 (20571)
2023 (22426)
2022 (26884)
2021 (27836)
2020 (23399)
2019 (16265)
2018 (11773)
2017 (13754)
2016 (11851)
2015 (14366)
2014 (10407)
2013 (7493)
2012 (7538)
2011 (7628)
2010 (7435)
Location
Africa (149)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17368)
Australia (2946)
California (4073)
Canada (1176)
China (378)
Colorado (153)
Connecticut (156)
Delaware (110)
Europe (37371)
Florida (498)
Georgia (124)
Idaho (16)
Illinois (240)
India (10)
Indiana (94)
Iowa (2)
Japan (79)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (495)
Massachusetts (3248)
Michigan (73)
Minnesota (152)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1011)
New Mexico (12)
New York (1090)
North Carolina (571)
North Dakota (5)
Northern California (1819)
Ohio (118)
Oklahoma (9)
Oregon (21)
Pennsylvania (770)
Puerto Rico (6)
Rhode Island (19)
South America (209)
South Carolina (5)
Southern California (1562)
Tennessee (25)
Texas (472)
United States (13917)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (362)
Wisconsin (16)
269,276 Results for "viewpoint therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Centerline Biomedical celebrates first on-label surgical case at the University of Virginia Health System with the 6Fr Viewpoint™ Catheter
November 20, 2024
·
2 min read
Business
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid.
July 5, 2023
·
4 min read
Defence’s Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines
September 5, 2023
·
4 min read
BioMidwest
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent.
January 23, 2023
·
3 min read
Deals
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.
September 28, 2022
·
4 min read
FDA
Centerline Biomedical receives FDA 510(k) clearance for new IOPS® Viewpoint Catheter, further addressing market need to reduce physician exposure to harmful x-ray radiation during image-guided, endovascular procedures
August 6, 2024
·
2 min read
Deals
Viewpoint Molecular Targeting Announces Transformational Merger
Viewpoint Molecular Targeting, Inc. today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy.
September 29, 2022
·
3 min read
Policy
Viewpoint Molecular Targeting Announces VMT-
Viewpoint Molecular Targeting, Inc. announced that the U.S. Food and Drug Administration has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors.
October 3, 2022
·
3 min read
Deals
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc.
February 6, 2023
·
5 min read
Business
Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer
Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer.
October 4, 2022
·
2 min read
1 of 26,928
Next
